fr   en
Clinical Studies

Tableaux synoptiques (en anglais)


Parcourir par date
Rechercher par mot clé
Date: 2010-01-08
Phase: I
Anouncement: Result
Biotech: Funxional Therapeutics (UK)
Pharma:
Product: FX125L - orally available small molecule - Broad Spectrum Chemokine Inhibitors (BSCIs)
Disease: inflammatory diseases
Country: USA
Other: Funxional Therapeutics Ltd has announced the successful completion of the Phase I programme of its novel anti-inflammatory, FX125L. Following the successful completion of the single ascending dose study in July 2009, a multiple ascending dose study, in which FX125L was administered orally once-daily in healthy subjects, was conducted also in the US.
This second Phase I study confirmed the excellent safety, tolerability and PK profile of FX125L and provided data consistent with an interaction of FX125L with its target receptor.
Complete results of the study will be presented in a future scientific meeting.
The company is now starting the preparation of the Phase II studies in differetn inflammatory conditions. These studies could be initiated in USA and Europe in the second quarter of 2010.